 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cambridge Investment Research Advisors Inc. lifted its stake in Biogen Inc. (NASDAQ:BIIB  Free Report) by 43.7% in the 2nd quarter, according to the company in its most recent Form 13F filing...

Cambridge Investment Research Advisors Inc. Purchases 4,612 Shares of Biogen Inc. (NASDAQ:BIIB)

Investors in Biogen Inc (BIIB) saw new options become available this week, for the April 2024 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is...

First Week of BIIB April 2024 Options Trading

Reata acquisition bolsters Biogen s rare disease portfolio with the addition of SKYCLARYS (omaveloxolone), the first and only FDA approved treatment for Friedreich s ataxia in the U.S. CAMBRIDGE...

Biogen Completes Acquisition of Reata Pharmaceuticals

Biogen Inc. (BIIB) Management presents at Decentralized Clinical Trials in Focus Conference (Transcript...

Biogen Inc. (BIIB) Management presents at Decentralized Clinical Trials in Focus Conference (Transcript)

First Trust Direct Indexing L.P. lifted its stake in Biogen Inc. (NASDAQ:BIIB  Free Report) by 8.2% in the second quarter, according to its most recent disclosure with the Securities and...

Biogen Inc. (NASDAQ:BIIB) Position Boosted by First Trust Direct Indexing L.P.

TOKYO and CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, Eisai ) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge...

LEQEMBI  Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer s Disease in Japan

An in-depth analysis of Biogen's intrinsic value and financial performanceRelated Stocks: BIIB...

Unveiling Biogen (BIIB)'s Value: Is It Really Priced Right? A Comprehensive Guide

Alta Wealth Advisors LLC raised its holdings in Biogen Inc. (NASDAQ:BIIB  Free Report) by 16.9% in the second quarter, according to its most recent 13F filing with the Securities &#38...

Alta Wealth Advisors LLC Acquires 262 Shares of Biogen Inc. (NASDAQ:BIIB)

Investors in Biogen Inc (BIIB) saw new options become available today, for the November 3rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options...

Interesting BIIB Put And Call Options For November 3rd

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Reata stockholders approve merger transaction with Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Watchers	18,628
52-Wk Low	$250.31
52-Wk High	$319.76

Market Cap	$37.29B
Volume (M)	11.00
52-Wk High	$319.76
52-Wk Low	$250.31

BIIB Biogen Inc

About

Feed

News

Sentiment

Earnings

Fundamentals